Regeneron Pharmaceuticals, Inc. (REGN) Financials
REGN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | 34.4 billion | 7.4 billion |
| 2023-12-31 | 33.1 billion | 7.1 billion |
| 2023-09-30 | 32.2 billion | 7.3 billion |
| 2023-06-30 | 30.7 billion | 6.6 billion |
REGN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | 1.4 billion | 230.1 million |
| 2023-12-31 | 776.2 million | 240.4 million |
| 2023-09-30 | 938.3 million | 203.9 million |
| 2023-06-30 | 909.4 million | 202.0 million |
REGN Net Income
Graph available only for supporters. Become a supporter to see it.
| Date | Net Income |
|---|---|
| 2024-03-31 | 722.0 million |
| 2023-12-31 | 1.2 billion |
| 2023-09-30 | 1.0 billion |
| 2023-06-30 | 968.4 million |
REGN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | 10.5 billion | - | 720.0 million |
| 2023-12-31 | 10.8 billion | - | 720.0 million |
| 2023-09-30 | 9.9 billion | - | 720.0 million |
| 2023-06-30 | 8.9 billion | 2.0 billion | 720.0 million |
REGN Shares Outstanding
REGN Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | 161.8 million | 1.1 billion | 689.0 million | - |
| 2023-12-31 | 313.5 million | 1.2 billion | 737.7 million | - |
| 2023-09-30 | 176.0 million | 1.1 billion | 640.5 million | - |
| 2023-06-30 | 113.0 million | 1.1 billion | 652.0 million | - |
REGN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 3.1 billion | 547.9 million |
| 2023-12-31 | 3.4 billion | 517.0 million |
| 2023-09-30 | 3.4 billion | 211.9 million |
| 2023-06-30 | 3.2 billion | 404.9 million |
REGN
Price: $957
52 week price:
Earnings Per Share: 34.76 USD
P/E Ratio: 27.12
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 417600
Ebitda: 597.4 millionMarket Capitalization: 105.4 billion